MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road von Caunt, Christopher J., Sale, Matthew J., Smith, Paul D., Cook, Simon J.

Volltext

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models von Winkler, Claudia, Armenia, Joshua, Jones, Gemma N., Tobalina, Luis, Sale, Matthew J., Petreus, Tudor, Baird, Tarrion, Serra, Violeta, Wang, Anderson T., Lau, Alan, Garnett, Mathew J., Jaaks, Patricia, Coker, Elizabeth A., Pierce, Andrew J., O’Connor, Mark J., Leo, Elisabetta

Volltext

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors von Sale, Matthew J., Minihane, Emma, Monks, Noel R., Gilley, Rebecca, Richards, Frances M., Schifferli, Kevin P., Andersen, Courtney L., Davies, Emma J., Vicente, Mario Aladren, Ozono, Eiko, Markovets, Aleksandra, Dry, Jonathan R., Drew, Lisa, Flemington, Vikki, Proia, Theresa, Jodrell, Duncan I., Smith, Paul D., Cook, Simon J.

Volltext

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance von Sale, Matthew J, Cook, Simon J

Volltext

Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation von Cope, Claire L, Gilley, Rebecca, Balmanno, Kathryn, Sale, Matthew J, Howarth, Karen D, Hampson, Mark, Smith, Paul D, Guichard, Sylvie M, Cook, Simon J

Volltext

Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance von Vasudevan, Harish N., Payne, Emily, Delley, Cyrille L., John Liu, S., Mirchia, Kanish, Sale, Matthew J., Lastella, Sydney, Nunez, Maria Sacconi, Lucas, Calixto-Hope G., Eaton, Charlotte D., Casey-Clyde, Tim, Magill, Stephen T., Chen, William C., Braunstein, Steve E., Perry, Arie, Jacques, Line, Reddy, Alyssa T., Pekmezci, Melike, Abate, Adam R., McCormick, Frank, Raleigh, David R.

Volltext

Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling von Cook, Simon J., Stuart, Kate, Gilley, Rebecca, Sale, Matthew J.

Volltext

Lysine Acetylation Controls Local Protein Conformation by Influencing Proline Isomerization von Howe, Françoise S., Boubriak, Ivan, Sale, Matthew J., Nair, Anitha, Clynes, David, Grijzenhout, Anne, Murray, Struan C., Woloszczuk, Ronja, Mellor, Jane

Volltext

The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stability von Sale, Matthew J, Cook, Simon J

Volltext

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance von Sale, Matthew J., Balmanno, Kathryn, Saxena, Jayeta, Ozono, Eiko, Wojdyla, Katarzyna, McIntyre, Rebecca E., Gilley, Rebecca, Woroniuk, Anna, Howarth, Karen D., Hughes, Gareth, Dry, Jonathan R., Arends, Mark J., Caro, Pilar, Oxley, David, Ashton, Susan, Adams, David J., Saez-Rodriguez, Julio, Smith, Paul D., Cook, Simon J.

Volltext

RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity von Castel, Pau, Dharmaiah, Srisathiyanarayanan, Sale, Matthew J., Messing, Simon, Rizzuto, Gabrielle, Cuevas-Navarro, Antonio, Cheng, Alice, Trnka, Michael J., Urisman, Anatoly, Esposito, Dominic, Simanshu, Dhirendra K., McCormick, Frank

Volltext

Inhibition and degradation of NRAS with a pan-NRAS monobody von Whaby, Michael, Ketavarapu, Gayatri, Koide, Akiko, Mazzei, Megan, Mintoo, Mubashir, Glasser, Eliezra, Patel, Unnatiben, Nasarre, Cecile, Sale, Matthew J., McCormick, Frank, Koide, Shohei, O’Bryan, John P.

Volltext

ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1 von Balmanno, Kathryn, Kidger, Andrew M, Byrne, Dominic P, Sale, Matthew J, Nassman, Nejma, Eyers, Patrick A, Cook, Simon J

Volltext

The ribosomal S6 kinase 2 (RSK2)–SPRED2 complex regulates the phosphorylation of RSK substrates and MAPK signaling von Lopez, Jocelyne, Bonsor, Daniel A., Sale, Matthew J., Urisman, Anatoly, Mehalko, Jennifer L., Cabanski-Dunning, Miranda, Castel, Pau, Simanshu, Dhirendra K., McCormick, Frank

Volltext

Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization von Young, Lucy C, Goldstein de Salazar, Ruby, Han, Sae-Won, Huang, Zi Yi Stephanie, Merk, Alan, Drew, Matthew, Darling, Joseph, Wall, Vanessa, Grisshammer, Reinhard, Cheng, Alice, Allison, Madeline R, Sale, Matthew J, Nissley, Dwight V, Esposito, Dominic, Ognjenovic, Jana, McCormick, Frank

Volltext

Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells von Little, Annette S, Balmanno, Kathryn, Sale, Matthew J, Newman, Scott, Dry, Jonathan R, Hampson, Mark, Edwards, Paul A W, Smith, Paul D, Cook, Simon J

Volltext

That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance von Sale, Matthew J, Cook, Simon J

Volltext

RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophy von Cuevas-Navarro, Antonio, Wagner, Morgan, Van, Richard, Swain, Monalisa, Mo, Stephanie, Columbus, John, Allison, Madeline R, Cheng, Alice, Messing, Simon, Turbyville, Thomas J, Simanshu, Dhirendra K, Sale, Matthew J, McCormick, Frank, Stephen, Andrew G, Castel, Pau

Volltext

Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction von Sale, Matthew J, Balmanno, Kathryn, Cook, Simon J

Volltext

Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells von Little, Annette S, Balmanno, Kathryn, Sale, Matthew J, Newman, Scott, Dry, Jonathan R, Hampson, Mark, Edwards, Paul A W, Smith, Paul D, Cook, Simon J

Volltext